SCHEMBL6719271

SCHEMBL6719271

Cc1ccccc1NC(=O)C(N)c1cccc(C(F)(F)F)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.60
KDM4E B2RXH2 1/20 0.54
HTT P42858 2/20 0.52
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
MAPT P10636 1/20 0.52
RAB9A P51151 1/20 0.52
KCNQ2 O43526 1/20 0.48
NPY5R Q15761 1/20 0.48
RXFP1 Q9HBX9 2/20 0.48
CYP1A2 P05177 2/20 0.47
CYP3A4 P08684 2/20 0.47
CYP2C9 P11712 2/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C19 P33261 1/20 0.47
ALDH1A1 P00352 1/20 0.46
POLB P06746 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
SLC1A3 P43003 1/20 0.46
SLC1A2 P43004 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6718687 0.81 RAB9A (0.55) GAAHTTMAPTRAB9ACYP1A2
SCHEMBL6718773 0.81 RAB9A (0.55) GAAHTTMAPTRAB9ACYP1A2
SCHEMBL28609335 0.81 RAB9A (0.55) GAAHTTMAPTRAB9ACYP1A2
SCHEMBL8227131 0.80 MEN1 (0.50) KDM4EHTTMEN1KMT2AMAPT
SCHEMBL6715577 0.78 LMNA (0.56) GAAHTTMAPTRAB9AKCNQ2
SCHEMBL17079632 0.76 DDX3X (0.73) GAAHTTMEN1KMT2AMAPT
SCHEMBL6715648 0.76 ALDH1A1 (0.67) KDM4EHTTMEN1KMT2AMAPT
SCHEMBL6715643 0.76 ALDH1A1 (0.67) KDM4EHTTMEN1KMT2AMAPT
Formic Acid SCHEMBL6717292 0.76 CYP1A2 (0.53) GAAHTTKMT2AMAPTRAB9A
Formic Acid SCHEMBL6715482 0.76 CYP1A2 (0.53) GAAHTTKMT2AMAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 US disclosed
WO-2004022534-A1 ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 WO disclosed
WO-2004022534-A1 ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors SLC1A2, SLC6A7, SLC1A1 GAA 136/4885KDM4E 3734/4885HTT 272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.